Go to content
UR Home

Kombinationstherapie der pulmonalarteriellen Hypertonie mit Vardenafil und Bosentan in einem ex-vivo/in-vitro-Setting

URN to cite this document:
urn:nbn:de:bvb:355-epub-415358
DOI to cite this document:
10.5283/epub.41535
Stadlbauer, Christian Thomas
Date of publication of this fulltext: 19 Feb 2020 08:36


Abstract (German)

Hintergrund: Die medikamentöse Behandlung der pulmonalarteriellen Hypertonie (PAH) setzt sich aus unterschiedlichen Substanzklassen zusammen, insbesondere Endothelin-Rezeptor-Antagonisten und Phosphodiesterase-5-Inhibitoren. In einer ex-vivo/in-vitro-Versuchsreihe wurden die vasorelaxierenden Effekte einer Kombinationstherapie aus Vardenafil (PDE-5-Inhibitor) und Bosentan (ET-1-Antagonist) mit ...

plus

Translation of the abstract (English)

Purpose: Phosphodiesterase 5 inhibitors and Endothelin receptor antagonists play an important part in the treatment of pulomary arterial hypertension (PAH). We established a human ex-vivo/in-vitro-model to compare the combined vasodilative effect of Vardenafil (PDE-5-inhibitor) and Bosentan (ERA) to their individual administration. Methods: We harvested short segments of pulmonary arteries (n=6) ...

plus


Owner only: item control page
  1. Homepage UR

University Library

Publication Server

Contact:

Publishing: oa@ur.de

Dissertations: dissertationen@ur.de

Research data: daten@ur.de

Contact persons